• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • Guideline for Pharmacovigilance Inspection in China

Guideline for Pharmacovigilance Inspection in China

Guideline for pharmacovigilance inspection
Monday, 25 April 2022 / Published in News, NMPA Registration in China, Pharmaceuticals & DMF

Guideline for Pharmacovigilance Inspection in China

Guideline for Pharmacovigilance Inspection in China has been issued (No.17-2022) by the National Medical Products Administration (NMPA) on April 15, 2022. The Quality Management Practice for Pharmacovigilance has been officially implemented (No.65-2021) since December 1, 2021, and the market authorization holders (MAHs) should have completed information registration in the national adverse drug reaction monitoring system as required. The NMPA regulatory document provides guidance to all provincial drug regulatory departments when carrying out pharmacovigilance inspections, and urges MAHs to implement the main responsibility of pharmacovigilance.

Guideline for Pharmacovigilance Inspection in China – Highlights

The new guideline for pharmacovigilance inspection in China has been reviewed and summarised by our regulatory experts below.

  • This regulatory guideline applies to the inspection of the pharmacovigilance activities carried out by MAH or commissioned by MAH by drug regulatory departments.
  • For drug registration applicants who are approved to conduct drug clinical trials, the drug regulatory department shall conduct pharmacovigilance inspections based on drug safety characteristics, clinical trial safety information reports and risk assessments, and initiate pharmacovigilance inspections during clinical trials or before marketing authorization.
  • This guideline sets out key considerations for routine and for-cause inspections, inspection method, inspection location, evaluation standard and inspection conclusion.
    • Key factors to be considered in routine inspections:
      • Characteristics of drugs
        • The safety characteristics of the drug.
        • Adverse drug reaction monitoring data and the occurrence of adverse drug reaction aggregation events.
        • Drugs with large sales volume or less substitute drugs.
        • Drugs with additional safety conditions when they are approved for marketing.
        • Innovative drugs, improved new drugs, and drugs for special groups such as children and pregnant women.
        • Drugs with high social concern.
      • Characteristics of the holder
        • Holders with more varieties and large sales volume.
        • Holders who have not undergone pharmacovigilance checks.
        • Holders who have obtained a drug registration certificate in China for the first time.
        • Holders who have major changes in the pharmacovigilance system or have a significant impact on the pharmacovigilance organizational structure due to mergers and acquisitions, organizational structure changes, etc.
        • Holder of entrusted production.
        • Holders commissioned to carry out pharmacovigilance activities.
      • Other circumstances
        • Previous pharmacovigilance examination or other examinations.
        • Other situations that the drug regulatory department deems it necessary to carry out inspections.
    • Key factors to be considered in the cause-based inspections:
      • Late reporting, concealment, or omission of suspected adverse drug reaction information, and the reporting quality is poor.
      • Monitoring of adverse drug reactions indicates that there may be safety risks.
      • Failure to discover, assess, control or communicate relevant risks in a timely manner.
      • Suspending production, sales, use and product recall, and failing to report to the drug regulatory authorities as required.
      • Failure to conduct post-marketing safety research, formulate and implement a pharmacovigilance plan as required by regulations or the requirements of drug regulatory authorities, and fail to provide explanations.
      • Failure to provide relevant information on pharmacovigilance as required by drug regulatory authorities or the information provided does not meet the requirements.
      • Delayed implementation or failure to fully implement corrective measures.
      • Other circumstances that require a cause-based inspection.
  • The organization and implementation of relevant inspection work shall be in accordance with the relevant requirements such as the “Notice of NMPA on Printing and Distributing the “Administrative Measures for Drug Inspection (Trial)” (No. 31-2021).

The National Medical Products Administration (NMPA) published the following regulatory documents in April 2022 also concerning post-market activities of drug products in China:

  • Administrative Measures for Drug Annual Reports (No.16-2022)

Read our separate blog post for more information on the Measures for the Supervision and Administration of Drug Production.

By Yu and Jacky. If you would like to learn more about Pharmacovigilance or our registration and CRO services for pharmaceuticals, medical devices, IVDs, cosmetics, health foods, industrial or consumer goods contact Cisema.

Tagged under: pharmacovigilance inspection

What you can read next

NMPA Finally Updates IVD Reagent Classification
China medical device standards management 2022
China medical device standards management 2022 annual report issued
Unique Identification for Medical Devices

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Physicochemical characterization of nanomaterials

    Physicochemical characterization of nanomaterials used in medical devices – New guidelines issued

    Physicochemical characterization of nanomateria...
  • Registration of disposable light-proof infusion sets in China

    Registration of disposable light-proof infusion sets in China – Amended guidelines issued

    Registration of disposable light-proof infusion...
  • Registration of disposable blood separation devices in China

    Registration of disposable blood separation devices in China – Amended guidelines issued

    Registration of disposable blood separation dev...
  • Registration of disposable infusion devices in China

    Registration of disposable infusion devices in China – Amended guidelines issued

    Registration of disposable infusion devices in ...
  • Registration of blood dialyzers in China

    Registration of blood dialyzers in China – Amended guidelines issued

    Registration of blood dialyzers in China shall ...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP